3
induced by various cancer chemotherapeutic agents, implying that concomitant administration of antioxidants may provide some relief. Cancer cell killing by these agents may utilize ROS-independent mechanisms (Fig. 1a) , implying that antioxidants may reduce cardiotoxicity without affecting the efficacy to kill cancer cells. However, whether antioxidants are useful for preventing cardiotoxicity during treatment with cancer therapeutic agents, particularly anthracyclines, has generated serious controversy, as ROS may also be involved in the mechanism of cytotoxicity toward cancer (Fig. 1b) . Unfortunately, with the exception of dexrazoxane, information on whether patients undergoing cancer chemotherapy and/or radiation therapy should receive either dietary or pharmacologic antioxidants is quite limited. whether patients should be given antioxidants during cancer treatment is unclear.
In addition, whether patients who have completed cancer treatment should receive antioxidants to prevent cardiotoxicity, which may occur years after the treatment, has not been addressed. Combination therapies, in particular with anthracyclines and trastuzumab, have also gained attention for serious concerns regarding cardiotoxicity [3] . whether antioxidants are effective in attenuating cardiotoxicity induced by trastuzumab or other cancer treatments, such as cisplatin and thoracic irradiation, is unclear. the present work revisits the issue on the role of antioxidant therapy in cardiotoxicity induced by cancer therapy in the era of cardio-oncology. there are clear needs for more research on the effects of antioxidants on cardiotoxicity induced by various antitumor drugs both at basic and at clinical levels, and we hope that this work will foster such effort to help develop optimal therapeutic strategies to treat cancer.
Definitions of ROS and antioxidants
while ROS can broadly be defined as any reactive molecules containing oxygen, in this article, we define ROS more strictly to include superoxide anion radical ( · O 2 − ), hydrogen peroxide (H 2 O 2 ), and hydroxyl radical (HO · ) as depicted in Fig. 2 . One-electron reduction of molecular oxygen (O 2 ) produces
− through various enzymatic and non-enzymatic mechanisms. Superoxide, once produced, can undergo a disproportionation reaction, in which one molecule of
− reacts with another · O 2 − molecule, leading to the formation of hydrogen peroxide at physiologic pH. this reaction is called dismutation and can be catalyzed by the class of enzymes called superoxide dismutases. Common targets of H 2 O 2 are cysteine thiolates. Hydrogen peroxide also serves as an electron source for the Fenton reaction in which reduced iron catalyzes the
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Cancer cell killing Cardiotoxicity B [41, 42] taxanes (paclitaxel, docetaxel) [69] 5-Fluorouracil [4, 46] Nitrogen mustard-alkylating agents (cyclophosphamide, ifosfamide, melphalan) [21, 27, 39, 74, 100] Cisplatin [67] trastuzumab [40, 76] Fludarabine [70] Mitomycin [10, 92] formation of HO · . Hydroxyl radicals are among the most potent ROS and can initiate lipid peroxidation, promote DNA oxidation, and induce protein oxidation, such as protein carbonylation. Superoxide and other reductants can donate an electron to oxidized iron to promote the Fenton reaction. Superoxide can also react with nitric oxide, thereby forming peroxynitrite. this would reduce the availability of nitric oxide and produce a potent oxidant peroxynitrite [29] .
In this article, we define the term "antioxidant" broadly as any molecules that are capable of inhibiting the formation, lifetime and actions of ROS. this definition could include (i) inhibitors of ROS-producing processes; (ii) scavengers of ROS themselves; (iii) scavengers of other reactive substances that may be produced in response to the actions and reactions of ROS; (iv) metal chelators; and (v) molecules that promote the expression of antioxidant proteins (Fig. 3) . the inhibitors of ROS-producing processes could include those that inhibit ROS-producing oxidases, such as NAD(P)H oxidase, xanthine oxidase, and monoamine oxidase. Many molecules have been shown to scavenge ROS. these include the scavengers of the highly reactive HO · , which will react with any organic compound with very high kinetic rate constants. Antioxidants may also scavenge and eliminate other reactive species that can be formed in response to ROS, such as lipid peroxides, other aldehydes, peroxynitrite, and hypochlorous acid. Chelators of metals that promote the Fenton reaction, and in particular, iron chelators can inhibit the formation of HO · . Finally, molecules that are capable of promoting gene expression of enzymes/proteins such as superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, thioredoxin, thioredoxin reductase, glutaredoxin, and peroxyredoxin, which increase the endogenous antioxidant defense system, have been recently recognized as potent mechanisms against ROS damage. Moreover, the transcription factor Nrf2 often regulates these processes [52] .
Mechanisms of cardiotoxicity by various antitumor drugs
In the modern era of combination therapy, it is important to evaluate the effects of multiple antitumor drugs that are capable of promoting cardiotoxicity. while anthracyclines are by far the most well-studied antitumor agents with regard to cardiotoxicity, experimental results suggest that other chemotherapeutic agents, such as cyclophosphamide, cisplatin, 5-fluorouracil, and trastuzumab, also exert cardiotoxicity through ROS. Here, we review the literature, which supports the hypothesis that antitumor drugs promote cardiotoxicity through the formation of ROS. therefore, antioxidants may protect the heart.
Anthracyclines
Anthracycline antibiotics derived from the bacteria Streptomyces peucetius var. caesius are widely used in cancer chemotherapy. Anthracyclines are composed of a tetracyclic ring structure attached to the sugar daunosamine and also have quinone and hydroquinone moieties, which allow them to act as electron-donating and electronaccepting agents (Fig. 4) Fig. 3 Definition of antioxidants. In the present work, the term "antioxidants" refers broadly to any molecules that have the capacity to inhibit the generation and action of ROS. these include (i) the inhibitors of oxidases (such as NADPH oxidase, xanthine oxidase, and monoamine oxidase), which may produce
(ii) small molecule and enzymatic scavengers of ROS; (iii) scavengers of other reactive species that are produced by ROS, such as lipid peroxides, other aldehydes, peroxynitrite, and hypochlorous acid; (iv) iron chelators that inhibit the Fenton reaction; and (v) molecules that act as nucleophiles to promote the expression of proteins with antioxidant capacities through mechanisms such as involvement of Nrf2 compound epirubicin are used for the treatment for solid tumors, such as breast adenocarcinoma or sarcomas, whereas daunorubicin and its related compound idarubicin are largely used for the treatment for acute leukemias [12] . Anthracyclines are known to be one of the most effective chemotherapy agents, which have been found to be therapeutically superior to other first-generation cancer chemotherapeutic agents, such as cyclophosphamide, fluorouracil, and methotrexate in the treatment for early-stage breast cancer [18] .
the therapeutic use of anthracyclines is limited due to the induction of debilitating cardiomyopathy and congestive heart failure. Acute cardiotoxicity and cardiac side effects that follow soon after induction therapy with anthracyclines can include St and t wave changes, tachycardia, cardiac arrhythmias, reduced ejection fraction, hypotension, and increased levels of troponin enzymes [48] . these effects are generally considered reversible [79] . Chronic cardiac side effects can include dilated cardiomyopathy and left ventricular failure [12] . these effects are considered irreversible and generally lead to a poor prognosis [79] . early post-mortem studies of patients treated with large doses of anthracyclines describe cardiac specimens as having degenerating myocardial cells, a decreased overall number of cells, and mitochondrial swelling [42] . Cardiac cell toxicity was found to be related to the cumulative dose of anthracyclines used. In a retrospective study of 399 patient records, heart failure reportedly occurred in 4 % of patients who received 500-550 mg/m 2 of doxorubicin, 18 % of patients who received 551-600 mg/m 2 , and 36 % of patients who received a dose >601 mg/m 2 [42] . limitations on cumulative lifetime doses of anthracyclines were subsequently set, and patients now rarely ever exceed a lifetime dose of 550 mg/m 2 of surface area. It is widely accepted that the oxidative stress placed on myocardial cells is likely the major contributing factor to the cardiotoxic effect. Anthracyclines have a high affinity for the phospholipid cardiolipin, which is concentrated in mitochondrial inner membranes. Because cardiac myocytes are relatively rich in mitochondria, anthracyclines accumulate in cardiac cells at higher concentrations than other cells of the body [25] . It is likely that in addition to compound accrual, additional cardiomyocyte-specific metabolism is involved in anthracycline cardiotoxicity. the quinone moiety of anthracycline undergoes redox cycling either in the presence of certain enzymes or in the presence of iron to produce ROS (Fig. 5 ). this oxidative stress leads to cardiac myocyte damage and dilated cardiomyopathy.
there are two major hypotheses for the mechanism of anthracycline-mediated production of ROS: (i) one-electron reduction of O 2 to form
− through redox cycling of semiquinone and (ii) one-electron reduction of O 2 to form
− by the anthracycline-iron complex (Fig. 5a ). In the cellular environment, the ring C of anthracyclines can be reduced to a semiquinone free radical by several flavoprotein oxidoreductases. Under normoxic conditions, the semiquinone free radical reduces O 2 to form (Fig. 5c ). Produced
− can then form other ROS and reactive species as described above, thereby leading to cellular damage.
In vitro and animal models have been conducted to evaluate the role of incorporating antioxidants with anthracyclines in the hopes of reducing oxidative damage to cardiac cells. early studies evaluated the effectiveness of common antioxidants found in the diet, which are known to prevent cellular oxidative damage. Many animal models showed a reduction in anthracycline cardiotoxicity by co-administering compounds such as vitamin e [23, 32, 51, 56, 60] , vitamin C [78] , vitamin A [87] , coenzyme Q [7, 13, 37] , and flavonoids [33, 89] . Other pharmaceutical compounds with known antioxidant properties, such as probucol [36, 45, 80] , carvedilol [55, 64] , and dantrolene [9] , have also been found to protect cardiac damage in animal models.
Much attention has been placed on the novel compound ICRF-187, which was later patented as dexrazoxane. Dexrazoxane can be hydrolyzed to an active metabolite (ADR-925) that is an iron chelate (Fig. 6) , thereby decreasing the amount of iron available to bind with anthracyclines and thus inhibiting the formation of ROS. early preclinical studies of ICRF-187 showed significantly reduced myocardial cell damage in animals co-administered dexrazoxane plus doxorubicin compared to doxorubicin alone [30, 31] . Human studies on this drug will be discussed later in this article.
trastuzumab (Herceptin)
Cell surface tyrosine kinase receptor HeR2 (also known as HeR2/neu and erbB2) functions as an oncogene in some malignancies, including breast, lung, and endometrial cancer [71, 82] . thus, the inhibition of this signaling pathway is considered as an effective means for cancer treatment. trastuzumab (Herceptin, produced by Genentech, CA), a monoclonal antibody that binds to HeR2, was approved by the FDA in 1998 for treating breast cancer and has been shown to improve survival of patients [83] . trastuzumab in combination with other chemotherapeutic agents, such as doxorubicin, increases both survival and response rate compared to trastuzumab alone [63] .
Although a combination therapy with doxorubicin and trastuzumab has significantly reduced the morbidity and mortality in breast cancer patients, cardiotoxicity remains as a serious concern. while cardiotoxicity by doxorubicin treatment is expected, the risk for developing cardiac dysfunction is higher when trastuzumab is used as adjuvant therapy with doxorubicin [93] . thus, agents that are capable of preventing cardiotoxicity in the setting of combination therapies would be useful.
the question that is addressed in this review article is whether ROS are involved and whether antioxidants may be useful for protecting the heart. It has been reported that activation of the HeR2 receptor by neuregulin-1 reduces anthracycline-induced oxidative stress in adult rat cardiomyocytes [88] (Fig. 7a) . therefore, the benefit of trastuzumab antagonism of neuregulin-1-HeR2 signaling in cancer cells may be offset by decreasing the ability of cardiomyocytes to withstand ROS. Gordon et al. [26] reported that the blockade of the neuregulin-1-erbB2 receptor interaction induced cardiomyocyte death through mitochondrial ROS production (Fig. 7b) . these results suggest that antioxidants may be useful for protecting the heart against toxicity induced by trastuzumab. Consistent with this, a murine study demonstrated that probucol attenuates cardiotoxicity induced by a combination of doxorubicin and trastuzumab [95] . In rats, melatonin (which is capable of scavenging reactive species such as HO · , H 2 O 2 , hypochlorous acid, and peroxynitrite), mercaptoethylguanidine (a compound that can inhibit inducible nitric oxide synthase and scavenges peroxynitrite) and 1,400 w (an inhibitor of inducible nitric oxide synthase) were all found to attenuate cardiotoxicity induced by a combination of doxorubicin and trastuzumab [66] . taxanes taxanes produced by the plants of the genus Taxus (yews), including paclitaxel (taxol) and docetaxel (taxotere), interfere with microtubule dynamics and are widely used as antitumor agents. A combination of doxorubicin and paclitaxel has been shown to be effective in treating breast cancer. while paclitaxel alone does not induced cardiotoxicity, taxanes and anthracyclines appear to synergize toxicity [69] . this synergy is thought to be due to the ability of taxanes to stimulate an enzymatic conversion of doxorubicin to its secondary alcohol metabolite doxorubicinol [72] . However, the levels of doxorubicin-derived ROS are not segmented by taxanes in human myocardial strips [73] . In adult rat ventricular myocytes, a minor increase in ROS production by paclitaxel or by anti-erbB2, as monitored by measuring dichlorofluorescein (DCF) fluorescence, was observed. However, no additive or synergistic effects by the two drugs were observed [68] .
Cyclophosphamide
Cyclophosphamide is a nitrogen mustard-alkylating agent, which adds an alkyl group to DNA, and has been widely used in the treatment for chronic and acute leukemia, multiple myeloma, and lymphomas [61] . Cyclophosphamideinduced cardiotoxicity was found also to be attenuated by antioxidants, including α-lipoic acid [62] and probucol [5] , in rats. A murine study demonstrated that while vitamin e has protective effects against doxorubicin-induced cardiotoxicity, these antioxidants did not provide protection against cardiotoxicity induced by a combination of doxorubicin and cyclophosphamide [8] . these results highlight the importance of understanding the effects of cardio-protectants in the setting of combination therapy.
Cisplatin
Cisplatin is the first member of a class of platinum-containing anti-cancer drugs. the platinum complexes kill cancer cells by crosslinking DNA. Cisplatin has broadly been used for the treatment for testicular, ovarian, cervical, bladder, and lung cancers. Cisplatin has been associated with cardiotoxicity as well as other side effects, such as nephrotoxicity [67] . various animal studies have suggested that compounds with antioxidant properties, such as resveratrol [96] , propionyl-l-carnitine [2] , α-lipoic acid [19, 34] , and proanthocyanidin [99] , attenuate cisplatin-induced cardiotoxicity.
5-Fluorouracil
5-Fluorouracil, a thymidylate synthase inhibitor, can exert cardiac side effects with an incidence of 1.2-7.6 % [4] . Recently, lamberti et al. [46] reported that 5-fluorouracil induces apoptosis of rat cardiac cell line through the generation of ROS. In rabbits, an antioxidant probucol was also found to protect 5-fluorouracil-induced endothelial damage [44] . In guinea pigs, 5-fluorouracil was found to decrease the activities of cardiac superoxide dismutase and glutathione peroxidase, while it increased the catalase activity [16] . Interestingly, in rats, 5-fluorouracil was found to inhibit doxorubicin-induced cardiotoxicity by reducing the levels of ROS [85] .
ROS and mechanisms of antitumor actions
In regard to mechanisms of cardiotoxicity that involve ROS, antioxidants that have the ability to inhibit the generation and actions of ROS are expected to be useful in protecting the heart during cancer chemotherapy. However, ROS may also be involved in the mechanism of antitumor drugs to kill cancer cells. thus, it has been generally speculated that the use of antioxidants may reduce the efficacy of these drugs to treat cancer, but the question remains as to whether ROS contribute to the anti-neoplastic effect of chemotherapeutic agents. the mechanism by which anthracyclines exhibit antitumor effects is likely multifactorial. these agents can interact directly with DNA by intercalating themselves within the planar ring structure and thereby mechanically block the process of DNA replication and RNA synthesis [17] . the intercalated anthracycline can also inhibit topoisomerase II, leading to apoptosis [12] . It has been suggested that tumor cells may become resistant to anthracyclines because of overexpression or altered expression of topoisomerase II [65] .
the degree to which ROS contribute to the anti-neoplastic effects of anthracyclines has been a source of controversy. Similar to the case in the heart, ROS could be generated by anthracyclines through either enzymatic or non-enzymatic pathways. In the presence of enzymes such as NADH dehydrogenase, cytochrome P450 reductases, or nitric oxide synthase, the quinone moiety of anthracyclines will be reduced to a semiquinone, which in turn can donate an election to molecular O 2 to form
− . the conversion of the quinone portion of anthracyclines can also be catalyzed non-enzymatically in the presence of iron through the formation of an anthracycline-iron complex that undergoes oxidation-reduction cycling and creates · O 2 − as a byproduct [77] . the accumulation of intracellular ROS has been shown to result in DNA strand degradation and breakage [6, 20] . However, many of the in vitro studies used greater intracellular concentrations of anthracyclines than those clinically utilized. while some studies have concluded that ROS do not contribute to anti-tumor effects of anthracyclines [43] , it remains unclear whether the clinical doses of anthracycline chemotherapy create a sufficient amount of oxidative stress to be toxic to tumor cells [24] .
Given the possibility that ROS formation may also contribute to the anti-neoplastic qualities of anthracyclines, early studies were also conducted to evaluate the efficacy of anthracyclines as a chemotherapy regimen when coadministered with antioxidant compounds. In most cases, the direct addition of antioxidants such as N-acetylcysteine [58, 59] , glutathione [98] , vitamin C [11, 78] , probucol [81] , ICRF-187 [97] , and carvedilol [64] to the cell culture did not reduce the anti-neoplastic efficacy of anthracyclines in a variety of tumor cells. this has been considered strong evidence indicating that ROS accumulation and oxidative stress is not the major mechanism by which anthracyclines kill cancer cells. Despite reports that the inhibition of erbB2 produces ROS in cancer cells [1, 14] , the use of antioxidants during trastuzumab therapy may be supported by the observations that a vitamin e analog can enhance the antitumor activity of trastuzumab [28] .
the heart may be more susceptible to ROS damage due to relatively low levels of antioxidant enzymes and because antitumor agents further reduce the levels of antioxidant enzymes. Cardiac muscle has been reported to contain 150 times less catalase and 4 times less superoxide dismutase than liver [15] . Doxorubicin also decreases glutathione peroxidase and manganese superoxide dismutase [47] .
Human clinical trials using antioxidants to protect against cardiotoxicity
Some human clinical trials have been conducted to test the hypothesis that co-administration of antioxidants with cancer chemotherapeutic agents protects the heart without reducing the efficacy of chemotherapy. these studies are summarized below. However, most of these studies were underpowered, and larger multicenter trials must be designed to provide a sufficient number of participants to effectively evaluate whether there is a benefit to these antioxidants. Furthermore, most of these studies examined the effects of anthracycline alone, and thus, information on combination therapies is lacking.
N-acetylcysteine
N-acetylcysteine is a precursor of glutathione, and its thiol moiety has been shown to reduce biological oxidants. Myers et al. [58] reported the results of a randomized controlled trial to evaluate combination chemotherapy with oral N-acetylcysteine. this study had a total enrollment of 54 adult patients with solid tumors: 30 in the control group who received 75 mg/m 2 of doxorubicin and 24 in the intervention group who received 5.5 mg/m 2 of N-acetylcysteine together with doxorubicin. Five patients in the intervention group refused to continue taking N-acetylcysteine secondary to nausea. After a 30-month follow-up, three patients in each group developed clinical heart failure (12.5 vs. 10 %, P = 0.77). No data on the tumor response rate between groups were collected.
Amifostine
Amifostine is an organic thiophosphate prodrug that is dephosphorylated by alkaline phosphatases in vivo to an active thiol-containing metabolite with antioxidant properties. A randomized controlled trial was conducted by Gallegos-Castorena et al. [23] to evaluate combination chemotherapy with amifostine infusions. twenty-eight pediatric patients with untreated osteosarcoma were enrolled: 13 in the control group received combination chemotherapy with cisplatin and doxorubicin 75 mg/m 2 , and 15 in the intervention group received 740 mg/m 2 amifostine infusion prior to chemotherapy infusion. At follow-up, two patients in the control group developed clinical heart failure compared to zero patients in the intervention group (P = 0.175). No data on the tumor response rate between groups were collected.
l-Carnitine l-Carnitine facilitates the transport of fatty acids into the mitochondrial matrix and can play a role in abating myocardial lipid peroxidation. waldner et al. [94] conducted a randomized controlled trial to evaluate combination chemotherapy with l-carnitine infusions. Forty adult patients with non-Hodgkin's lymphomas were randomly assigned to a study group: 20 in the control group received six cycles of CHOP therapy that included doxorubicin 50 mg/m 2 , and 20 in the intervention group received an additional infusion of 3 g l-carnitine before chemotherapy. No patients in the control or intervention groups developed heart failure, and there was no significant difference in the left ventricular ejection fraction according to echocardiography following completion of six chemotherapy cycles. Additionally, there was no difference in the quality of life between the two study groups according to a standardized questionnaire. No data on the tumor response rate between groups were collected.
Carvedilol
Carvedilol is a cardioselective beta-blocker with antioxidant properties. A randomized controlled trial has been conducted evaluating combination chemotherapy with oral carvedilol [38] . Fifty adult patients with newly diagnosed solid tumors were enrolled: 25 in the control group received anthracycline-based chemotherapy and 25 in the intervention group received 12.5 mg oral carvedilol during and following chemotherapy. One patient in the control group and no patients in the intervention group developed clinical heart failure (P = 1). Five patients in the control group and one patient in the intervention group developed subclinical heart failure as defined by echocardiography results (P = 0.13). No data on the tumor response rate between groups were collected.
Coenzyme Q10
Iarussi et al. [35] reported results of a randomized controlled trial evaluating combination chemotherapy with oral coenzyme Q10. twenty pediatric patients with either solid tumor or leukemia were enrolled: 10 patients in the control group received doxorubicin and 10 patients in the intervention group received 100 mg oral coenzyme Q10 twice daily during chemotherapy. No patients developed clinical or subclinical heart failure in either the control or intervention groups. No data on the tumor response rate between groups were collected.
Dexrazoxane
Seven randomized controlled trials have been conducted evaluating combination chemotherapy with oral dexrazoxane [48, 50, 54, 75, 84, 86, 91] . Data from these studies were recently pooled for a meta-analysis through a Cochrane review [90] . Among these studies, a total of 1,561 patients were enrolled: 792 were assigned to a control group receiving anthracycline-based chemotherapy and 769 patients were assigned to the intervention group receiving Iv infusion of dexrazoxane at a varying dose of 10:1 or 20:1 ratio of study drug to doxorubicin. Sixty-nine patients in the control groups developed clinical heart failure compared with 11 patients in the intervention group (P < 0.00001, RR 0.18, 95 % CI 0.10-0.32).
the Cochrane group was also able to pool data on tumor response rates from five trials [50, 54, 84, 86, 91] . these studies used standardized wHO criteria to evaluate clinical response to chemotherapy. Among 518 patients in the control groups, 260 reported complete or partial response to chemotherapy, and among 503 patients in the intervention groups with dexrazoxane, 223 patients reported complete and partial responses (P = 0.08). Additionally, when survival data were pooled from three trials [54, 84, 86] , no significant difference between the control and intervention groups was found in terms of overall or progression-free survival.
Melatonin lissoni et al. [49] conducted a human study to investigate the effects of daily oral administration of melatonin on clinical outcomes of chemotherapeutic agents given to 250 patients with various cancers. Chemotherapeutic agents consisted of cisplatin plus etoposide or gemcitabine alone for lung cancer, doxorubicin alone, mitoxantrone alone, or paclitaxel alone for breast cancer, 5-fluorouracil plus folinic acid for gastrointestinal tumors, and 5-fluorouracil plus cisplatin for head and neck cancer. After 1-year followup, the survival rate was found to be significantly higher in patients who were concomitantly treated with melatonin with therapeutic agents. the concomitant administration of melatonin also significantly reduced the frequency of side effects, including cardiotoxicity.
Limitations of existing human data
Cardiotoxicity of anthracycline-based chemotherapy remains a significant challenge and is the reason why lifetime cumulative dosing of these drugs has been limited. to date, the only compound to successfully reduce the incidence of heart failure has been the iron chelate dexrazoxane. However, despite improved clinical pictures of these patients and improved quality of life scores, controlled trials have not been able to show a survival benefit for patients co-treated with dexrazoxane. the vast majority of deaths in these trials were due to complications associated with the progression of cancer, such as pulmonary emboli and sepsis. Based on the early investigations and more recent clinical trials, it is clear that anthracyclines are one of the most effective induction chemotherapies and that their anti-neoplastic cytotoxicity improves with increased dosing [18] .
Future controlled trials with dexrazoxane are needed to compare larger doses of anthracycline chemotherapy plus dexrazoxane to current doses of anthracycline chemotherapy plus dexrazoxane. At this point, dosing of anthracyclines is limited to less than 550 mg/m 2 because early investigations showed that dosing above this amount increases the risk of clinical heart failure to as high as 18 % [42] . However, given that trials showed dexrazoxane significantly reduces the risk of clinical heart failure, that increased doses of anthracyclines contribute to increased anti-neoplastic cytotoxicity, and that survival seems to be related more to the complications of progressive cancer rather than heart failure, increasing the cumulative dose of anthracyclines to above 550 mg/m 2 plus dexrazoxane may increase the incidence of heart failure, but would also be a more effective chemotherapy regimen and increase overall survival.
Dexrazoxane trials should also be extended to examine its effects on other antitumor drugs, particularly when they are used in combination with agents such as anthracyclines. In the modern era, it is critical to understand the effects of dexrazoxane on patients who have completed chemotherapy to assess its long-term effects. this may be a challenge, given the side effects and discomfort that dexrazoxane exerts on patients. In this regard, the use of antioxidants with fewer side effects would be an attractive approach.
Randomized controlled trials on other common compounds with antioxidant properties have been limited. None of the trials that examined the effectiveness of l-carnitine, amifostine, carvedilol, or coenzyme Q10 on anthracyclines showed a reduction in heart failure. However, all of these studies were underpowered. larger multicenter trials must be designed to provide a sufficient number of participants to effectively evaluate whether these antioxidant compounds provide a benefit. In addition to suffering from low statistical power, the randomized clinical trial investigating N-acetylcysteine was also hindered by poor patient compliance. Five patients out of twenty-four patients in the intervention group could not tolerate ingesting the study drug secondary to nausea. thus, future, large randomized clinical trials may investigate an Iv infusion of N-acetylcysteine as a method of delivering this antioxidant.
It is especially notable that no randomized clinical trials have been published as yet evaluating probucol as a possible cardioprotectant. this drug has fallen out of favor as a lipidlowering agent due to undesirable decreases in high-density lipoprotein. However, it has been shown to have strong antioxidant properties in vitro [53] . Animal models have also shown it to be effective at preventing the development of anthracycline-induced cardiomyopathy while not affecting the anti-neoplastic toxicity of anthracyclines [81] . In addition, probucol was found to attenuate cardiotoxicity induced by a combination of doxorubicin and trastuzumab in mice [95] .
An important consideration for antioxidant intervention is the latency period during the development of anthracycline cardiotoxicity. therefore, it may be possible to uncouple initial anti-neoplastic toxicity from secondary progression of damage to the heart through a post-anthracycline treatment regimen of putative cardioprotective antioxidants. Moreover, trials should be designed to measure plasma levels of antioxidants to account for individual variability in absorption and metabolism during this phase. In this regard, responses may be stratified based on the effective concentrations of antioxidant in plasma, rather than solely on whether a subject had ingested the compound relative to control.
Conclusions
Recent success of cancer chemotherapy with combination therapy has raised the old argument on whether cancer patients should receive dietary and/or pharmacologic antioxidants. whether antioxidants adversely affect the cancer cell killing function of chemotherapeutic agents while exerting cardioprotective effects in humans remains unclear. A critical question that still remains is whether patients who have completed chemotherapy should receive antioxidants. the answer to this question will remain unknown until welldesigned randomized clinical trials are conducted.
